A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)

A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)

Objectives: Imipenem/cilastatin/relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor combination effective against gram-negative pathogens. Efficacy and safety of IMI/REL were studied in critically ill adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pn...

Full description

Saved in:
Bibliographic Details
Main Authors: Junjie Li, Feng Wei, Peng Xiang, Zhengang Tang, Lianshu Ding, Luke Francis Chen, Maria Losada, Zlatka Iamboliyska, Fang Sun, Mingfen Zhu, Xiaodan Guo, Xiaoling Du, Chang Chen, Christopher Bruno, Sandra Koseoglu, Katherine Young, Min Zhou, Jieming Qu
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:International Journal of Infectious Diseases
Subjects:
Gram-negative bacteria
Multidrug resistance
Nosocomial infection
Pneumonia
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971224004326
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1201971224004326

Similar Items